The aim of the study is to create new tools for improving management of patients with hematological malignancies by combining extensive clinical data from patients newly diagnosed with hematological malignancies and innovative laboratory analyses made on available tissue samples in regional biobanks from these patients.
Firstly, clinical information is collected on all hematological malignancies diagnosed in our hospital district area retrospectively between the years 2000 and 2019. Clinical outcomes, laboratory results, clinically relevant diagnoses, characteristics defining clinical stage and established prognostic parameters are gathered. Simultaneously a tissue microarray (TMA) of diagnostic samples is compiled using representative annotated tissue areas. This TMA is used in combination with additional control material to identify prognostic and predictive biomarkers. A combined microarray dataset of hematological malignancies (Hemap) is utilized to point out genes of possible drug targets, disease specific markers, prognostic markers, or predictive markers. The clinical datasets and Hemap dataset is ultimately utilized to gain knowledge, new tools for prognostication and diagnostics, and targets for treatment. Artificial intelligence -assisted differential diagnostics will be tested.
Study Type
OBSERVATIONAL
Enrollment
5,000
Tampere Univerisity Hospital
Tampere, Finland
Progression-free survival (PFS)
Time from the first line treatment for hematological malignancy until the date of first documented relapse or transformation or death of any cause, whichever came first, assessed up to the end of the study period (April 2019).
Time frame: From the first line treatment up to the end of the study period (April 2019).
Overall survival (OS)
Survival time from the diagnosis of hematological malignancy until the date of death of any cause, assessed up to the end of the study period (April 2019).
Time frame: From the diagnosis up to the end of the study period (April 2019).
Response to treatment
Best response to the first line treatment for the hematological malignancy, according to malignancy in question, e.g. complete response (CR), stringent complete response (sCR), partial response (PR), very good partial response (VGPR), stable disease (SD), progressive disease (PD), treatment failure, clinical response, hematological response etc.
Time frame: From the first line treatment up to the end of the study period (April 2019).
Event-free survival (EFS)
Survival time from the first line treatment for hematological malignancy until any primary event (death, relapse, disease progression/transformation, secondary malignancy, resistant disease etc.), whichever came first, assessed up to the end of the study period (April 2019).
Time frame: From the first line treatment up to the end of the study period (April 2019).
Sepsis or other life-threatening infection
Fulminant infection after diagnosis
Time frame: From the first line treatment up to the end of the study period (April 2019).
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Multiple organ failure
Altered organ function in acutely ill patient
Time frame: From the first line treatment up to the end of the study period (April 2019).
Thrombo-embolism
Venous thromboembolism
Time frame: From the first line treatment up to the end of the study period (April 2019).
Disease transformation
Hematological malignancy transforms into another malignancy
Time frame: From the diagnosis up to the end of the study period (April 2019).
ICU admission
Admission to intensive care unit
Time frame: From the first line treatment up to the end of the study period (April 2019).
Adverse effects
Treatment-related adverse effects/events
Time frame: From the first line treatment up to the end of the study period (April 2019).
Secondary malignancy
Secondary malignancy after the diagnosis of hematological malignancy
Time frame: From the first line treatment up to the end of the study period (April 2019).
Relapse
Relapse after or during the treatment.
Time frame: From the first line treatment up to the end of the study period (April 2019).
Complete remission
Complete remission after the treatment
Time frame: From the first line treatment up to the end of the study period (April 2019).
Time to complete remission
Time to complete remission
Time frame: From the first line treatment up to the end of the study period (April 2019).
Best response
Best response e.g. hematological remission, molecular remission, radiological remission
Time frame: From the first line treatment up to the end of the study period (April 2019).
Time to best response
Time to best response e.g. hematological remission, molecular remission, radiological remission
Time frame: From the first line treatment up to the end of the study period (April 2019).